MX2012014986A - Sintesis y uso de inhibidores de cinasa. - Google Patents

Sintesis y uso de inhibidores de cinasa.

Info

Publication number
MX2012014986A
MX2012014986A MX2012014986A MX2012014986A MX2012014986A MX 2012014986 A MX2012014986 A MX 2012014986A MX 2012014986 A MX2012014986 A MX 2012014986A MX 2012014986 A MX2012014986 A MX 2012014986A MX 2012014986 A MX2012014986 A MX 2012014986A
Authority
MX
Mexico
Prior art keywords
synthesis
fak
based catalyst
kinase inhibitors
reactions
Prior art date
Application number
MX2012014986A
Other languages
English (en)
Other versions
MX343894B (es
Inventor
Yixiong Lei
Carl Henry Behrens
Hui-Yin Li
Connie L Sun
Original Assignee
Poniard Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poniard Pharmaceuticals Inc filed Critical Poniard Pharmaceuticals Inc
Publication of MX2012014986A publication Critical patent/MX2012014986A/es
Publication of MX343894B publication Critical patent/MX343894B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La presente invención se refiere a una síntesis mejorada de una clase de inhibidor de la cinasa de Adhesión Focal (FAK), en donde se reduce el uso de un catalizador a base de paladio extensivo y se mejoran los rendimientos de la reacción y purezas del producto. Se optimizan las dos reacciones clave de acoplamiento de haluro de arilo con anilina con el descubrimiento sorprendente de que los catalizadores a base de paladio pueden ser dispensados completamente en una de las reacciones. La invención también proporciona el uso de los compuestos inhibidores de FAK en el tratamiento de trastornos inflamatorios e inmunes de artritis.
MX2012014986A 2010-06-30 2011-06-28 Síntesis y uso de inhibidores de cinasa. MX343894B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35994210P 2010-06-30 2010-06-30
PCT/US2011/042169 WO2012012139A1 (en) 2010-06-30 2011-06-28 Synthesis and use of kinase inhibitors

Publications (2)

Publication Number Publication Date
MX2012014986A true MX2012014986A (es) 2013-07-03
MX343894B MX343894B (es) 2016-11-28

Family

ID=45497129

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012014986A MX343894B (es) 2010-06-30 2011-06-28 Síntesis y uso de inhibidores de cinasa.

Country Status (10)

Country Link
US (1) US9505719B2 (es)
EP (1) EP2588476A4 (es)
JP (1) JP5923499B2 (es)
CN (1) CN103168037A (es)
AU (1) AU2011280031B2 (es)
CA (1) CA2803005A1 (es)
MX (1) MX343894B (es)
NZ (1) NZ604801A (es)
WO (1) WO2012012139A1 (es)
ZA (1) ZA201300012B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2691673T3 (es) 2011-02-17 2018-11-28 Cancer Therapeutics Crc Pty Limited Inhibidores de Fak
DK2675794T3 (da) 2011-02-17 2019-05-06 Cancer Therapeutics Crc Pty Ltd Selektive fak-inhibitorer
WO2019117813A1 (en) * 2017-12-15 2019-06-20 National University Of Singapore Focal adhesion kinase targeted therapeutics for the treatment of glaucoma and fibrosis

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656182A (en) * 1983-12-06 1987-04-07 Warner-Lambert Company Substituted trans-1,2-diaminocyclohexyl amide compounds
US20040006005A1 (en) 2002-07-02 2004-01-08 Sanjay Bhanot Use of integrin-linked kinase inhibitors for treating insulin resistance, hyperglycemia and diabetes
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
JP4593074B2 (ja) 2000-10-11 2010-12-08 セフアロン・インコーポレーテツド モダフィニル化合物含有組成物
AR040456A1 (es) * 2002-06-27 2005-04-06 Bristol Myers Squibb Co Piridina n-oxidos 2,4 -disubstituidos utiles como inhibidores de transcriptasa inversa del virus de inmunodeficiencia humana
US20080119515A1 (en) 2003-03-10 2008-05-22 M Arshad Siddiqui Heterocyclic Kinase Inhibitors: Methods of Use and Synthesis
GT200500310A (es) 2004-11-19 2006-06-19 Compuestos organicos
MX2007010051A (es) 2005-02-18 2007-09-21 Tibotec Pharm Ltd Derivados de oxido de 2-(4-cianofenilamino)pirimidina que inhiben el virus de inmunodeficiencia humana.
CA2626579A1 (en) 2005-10-25 2007-05-03 Abbott Laboratories Formulation comprising a drug of low water solubility and method of use thereof
CA2650395A1 (en) * 2006-04-28 2007-11-08 Schering Corporation Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same
CN101495095B (zh) * 2006-04-28 2013-05-29 默沙东公司 通过受控的沉淀来沉淀和分离6,6-二甲基-3-氮杂-双环[3.1.0]己烷-酰胺化合物的方法和含有其的药学制剂
CA2657346A1 (en) 2006-07-21 2008-01-24 Novartis Ag Formulations for benzimidazolyl pyridyl ethers
ES2485040T3 (es) * 2007-03-16 2014-08-12 The Scripps Research Institute Inhibidores de cinasa de adhesión focal
US20090203709A1 (en) 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor
WO2009105498A1 (en) * 2008-02-19 2009-08-27 Smithkline Beecham Corporation Anilinopyridines as inhibitors of fak
ES2472323T3 (es) * 2008-06-17 2014-06-30 Astrazeneca Ab Compuestos de piridina
JP2013501808A (ja) 2009-08-12 2013-01-17 ポニアード ファーマシューティカルズ， インコーポレイテッド アポトーシスを促進し、かつ転移を阻害する方法
WO2011133668A2 (en) 2010-04-20 2011-10-27 President And Fellows Of Harvard College Methods and compositions for the treatment of cancer

Also Published As

Publication number Publication date
CA2803005A1 (en) 2012-01-26
MX343894B (es) 2016-11-28
AU2011280031B2 (en) 2015-09-10
WO2012012139A1 (en) 2012-01-26
US20140235635A1 (en) 2014-08-21
JP2013529687A (ja) 2013-07-22
ZA201300012B (en) 2013-09-25
AU2011280031A1 (en) 2013-01-10
EP2588476A4 (en) 2014-07-23
CN103168037A (zh) 2013-06-19
US9505719B2 (en) 2016-11-29
JP5923499B2 (ja) 2016-05-24
EP2588476A1 (en) 2013-05-08
NZ604801A (en) 2015-03-27

Similar Documents

Publication Publication Date Title
MX348623B (es) Proceso y sistema de reaccion para la preparacion de metanol.
WO2012054364A3 (en) Bicyclic diamines as janus kinase inhibitors
MX2015000129A (es) Derivados de pirimidin pirazolilo.
MY162806A (en) Organo-catalytic biomass deconstruction
PH12014502775A1 (en) TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS
WO2012135113A3 (en) Cyclopropylamines as lsd1 inhibitors
MX361279B (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas.
MX2012003770A (es) Metodos para la modulacion de autofagia a traves de la modulacion de productos de genes que aumentan la autofagia.
JO3450B1 (ar) أشكال جرعات تحرير جديدة معدلة لمثبطات زانثين اوكسيدوريدوكتيز أو مثبطات زانثين اوكسيديز
MX351657B (es) Sales de alcaloide de cinchona bis-cuaternarias como catalizadores de transferencia de fase asimétrica.
MX349801B (es) Sustratos de enzimas de ácido nucleico.
MX2015006335A (es) Produccion de poliolefina con multiples reactores de polimerizacion.
ZA201002078B (en) Bubble column type hydrocarbon synthesis reactor,and hydrocarbon synthesis reaction system having the same
MX2012014986A (es) Sintesis y uso de inhibidores de cinasa.
IN2012DN00459A (es)
PH12017500270A1 (en) Use of 1-phenyl-3-dimethylaminopropane compounds for treating rheumatoid pain
IN2015DN02588A (es)
BR112014019356A8 (pt) Método para produzir um ou mais produtos finais de fermentação e produto final de fermentação
EP3958942A4 (en) PORTABLE OXYGEN PRODUCTION SYSTEM
WO2011113895A3 (en) Characterization and validation of inhibitors and ligands of dipeptidyl aminopeptidase iv (dp iv)
MD3996C2 (ro) Percloraţi de 5-R-saliciliden-4-feniltiosemicarbazonato(1-)-aquacupru(II) ce posedă proprietăţi de inhibitori ai activităţii enzimei 17 b-HSD (tipul 1)
MX2009004628A (es) Sal de alisquireno con acido orotico.
IT1397233B1 (it) Procedimento migliorativo per la sintesi del mono-acetil ganciclovir, intermedio chiave per la sintesi del valganciclovir.
WO2013184570A3 (en) Synthesis of 1,3-substituted aminouracils and other xanthine-related compounds
HK1208882A1 (en) New process for the production and purification of the collagenase enzyme from vibrio alginolyticus (vibrio alginolyticus)

Legal Events

Date Code Title Description
FG Grant or registration